Approved by the FDA in August 2023, zuranolone (branded Zurzuvae) has been released and is the first oral medication to treat postpartum depression. Zuranolone supplies a mimic of allopregnanolone – a neurohormone that decreases significantly after pregnancy to help reverse the withdrawal effects that impact mood.
